# EMPOWER-Lung 3 (NCT03409614)

> Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

No report yet. It can be ordered.

- Drugs tested: cemiplimab
- Indication: first-line advanced or metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03409614
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Regeneron Pharmaceuticals
- Conditions: Non-small Cell Lung Cancer
- Interventions: REGN2810; REGN2810/chemo/ipi; Chemotherapy; Placebo
- Enrollment: 789
- Primary outcome: Part 1: Overall Survival (OS)
- Primary outcome: Part 2: OS

## Indexed commentary on EMPOWER-Lung 3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 20
- YouTube: 19
- X threads: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=empower-lung-3-nct03409614

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03409614", "email": "<work email>"}; the inbox owner confirms by the emailed link.